Skip to main content

DeCode Announces SNP Discovery, Reiterates Revenue Projections

NEW YORK, July 1 - DeCode Genetics announced progress in several areas of its population genetics and target discovery research today, while reiterating that it will meet its revenue and cash-burn goals for the year.

 

The Reykjavik, Iceland, company announced in connection with an investor meeting that it had identified a set of SNPs on chromosome 5 that increases the risk of stroke by two-fold, and another one that doubles the risk of type 2 diabetes.

 

The company also said it had confirmed an earlier finding of a genetic mutation that increased risk for osteoporosis in studies outside Iceland. DeCode said it would receive milestone payments from its partner, Roche, on these findings.

 

DeCode additionally said that small-molecule lead discovery programs for schizophrenia, atherosclerosis, and peripheral arterial occlusive disease are progressing, and that it had identified a novel kinase target for asthma.

 

The company said it expects to receive $45 million in revenue for the year under its current contracts, and to burn $20 million in cash. The company had $93.2 million in cash and cash equivalents at the end of 2002.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.